Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates

Science Translational Medicine

Volumn 2, Issue 37, 2010, Pages

  Tucker, Erik I ^a   Marzec, Ulla M ^a   Berny, Michelle A ^a   Hurst, Sawan ^a   Bunting, Stuart ^b   McCarty, Owen J T ^a   Gruber, András ^a,c   Hanson, Stephen R ^a,c  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NEUTRALIZING ANTIBODY; THROMBOPOIETIN; THROMBOPOIETIN ANTIBODY; UNCLASSIFIED DRUG; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BABOON; BLEEDING TIME; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GRAFT OCCLUSION; HEART INFARCTION; HEMOSTASIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPOIESIS; ANIMAL; BLOOD; BLOOD VESSEL PROSTHESIS; DRUG ANTAGONISM; HEART ARREST; PATHOLOGY; STROKE; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; ANTITHROMBINS; BLEEDING TIME; BLOOD VESSEL PROSTHESIS; HEART ARREST; HUMANS; MALE; PAPIO; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; STROKE; THROMBOPOIETIN; THROMBOSIS; TREATMENT OUTCOME;

EID: 77955591757     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000697     Document Type: Article

References (57)

1. Z. M. Ruggeri, Platelets in atherothrombosis. Nat. Med. 8, 1227-1234 (2002).
2. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348, 1329-1339 (1996).
3. D. L. Bhatt, K. A. Fox, W. Hacke, P. B. Berger, H. R. Black, W. E. Boden, P. Cacoub, E. A. Cohen, M. A. Creager, J. D. Easton, M. D. Flather, S. M. Haffner, C. W. Hamm, G. J. Hankey, S. C. Johnston, K. H. Mak, J. L. Mas, G. Montalescot, T. A. Pearson, P. G. Steg, S. R. Steinhubl, M. A. Weber, D. M. Brennan, L. Fabry-Ribaudo, J. Booth, E. J. Topol; CHARISMA Investigators, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
4. S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F. J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, J. Riesmeyer, G. Weerakkody, C. M. Gibson, E. M. Antman; TRITON-TIMI 38 Investigators, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
5. E. J. Topol, D. J. Moliterno, H. C. Herrmann, E. R. Powers, C. L. Grines, D. J. Cohen, E. A. Cohen, M. Bertrand, F. J. Neumann, G. W. Stone, P. M. DiBattiste, L. Demopoulos; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial, Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 344, 1888-1894 (2001).
6. M. F. Buckley, J. W. James, D. E. Brown, G. S. Whyte, M. G. Dean, C. N. Chesterman, J. A. Donald, A novel approach to the assessment of variations in the human platelet count. Thromb. Haemost. 83, 480-484 (2000).
7. H. Q. Ly, A. J. Kirtane, S. A. Murphy, J. Buros, C. P. Cannon, E. Braunwald, C. M. Gibson; TIMI Study Group, Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am. J. Cardiol. 98, 1-5 (2006).
8. E. Thaulow, J. Erikssen, L. Sandvik, H. Stormorken, P. F. Cohn, Blood platelet count and function are related to total and cardiovascular death in apparently healthymen. Circulation 84, 613-617 (1991).
9. R. Iijima, G. Ndrepepa, J. Mehilli, O. Bruskina, S. Schulz, A. Schömig, A. Kastrati, Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb. Haemost. 98, 852-857 (2007).
10. E. Nikolsky, C. L. Grines, D. A. Cox, E. Garcia, J. E. Tcheng, M. Sadeghi, R. Mehran, A. J. Lansky, Y. Na, G. W. Stone, Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am. J. Cardiol. 99, 1055-1061 (2007).
11. M. P. Turakhia, S. A. Murphy, T. L. Pinto, E. M. Antman, R. P. Giugliano, C. P. Cannon, E. Braunwald, C. M. Gibson; Thrombolysis in Myocardial Infarction Study Group, Association of platelet count with residual thrombus in themyocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acutemyocardial infarction. Am. J. Cardiol. 94, 1406-1410 (2004).
12. S. R. Hanson, S. J. Slichter, Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood 66, 1105-1109 (1985).
13. J. N. George, Platelets. Lancet 355, 1531-1539 (2000).
14. D. B. Cines, V. S. Blanchette, Immune thrombocytopenic purpura. N. Engl. J. Med. 346, 995-1008 (2002).
15. R. McMillan, Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann. Intern. Med. 126, 307-314 (1997).
16. J. N. George, M. A. el-Harake, G. E. Raskob, Chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 331, 1207-1211 (1994).
17. L. T. Goodnough, M. F. Johnston, G. Ramsey, M. H. Sayers, R. S. Eisenstadt, K. C. Anderson, R. C. Rutman, L. E. Silberstein, Guidelines for transfusion support in patients undergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Ann. Thorac. Surg. 50, 675-683 (1990).
18. B. D. Spiess, B. S. Gillies, W. Chandler, E. Verrier, Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J. Cardiothorac. Vasc. Anesth. 9, 168-173 (1995).
19. S. Vanderschueren, A. De Weerdt, M. Malbrain, D. Vankersschaever, E. Frans, A. Wilmer, H. Bobbaers, Thrombocytopenia and prognosis in intensive care. Crit. Care Med. 28, 1871-1876 (2000).
20. S. Cortelazzo, G. Finazzi, M. Ruggeri, O. Vestri, M. Galli, F. Rodeghiero, T. Barbui, Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332, 1132-1136 (1995).
21. S. Moore, R. J. Friedman, D. P. Singal, J. Gauldie, M. A. Blajchman, R. S. Roberts, Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb. Haemost. 35, 70-81 (1976).
22. I. Reyers, L.Mussoni, M. B. Donati,G. deGaetano, Severe thrombocytopenia delays but does not prevent the occlusion of an arterial prosthesis in rats. Thromb. Haemost. 46, 558-560 (1981).
23. S. Lockyer, J. Kambayashi, Demonstration of flow and platelet dependency in a ferric chloride-induced model of thrombosis. J. Cardiovasc. Pharmacol. 33, 718-725 (1999).
24. J. M. Herbert, A. Bernat, J. P. Maffrand, Importance of platelets in experimental venous thrombosis in the rat. Blood 80, 2281-2286 (1992).
25. Y. Merhi, J. Y. Lam, L. L. Lacoste, J. G. Latour, R. Guidoin, D. Waters, Effects of thrombocytopenia and shear rate on neutrophil and platelet deposition on endothelial and medial arterial surfaces. Arterioscler. Thromb. 13, 951-957 (1993).
26. R. L. Basser, E. O'Flaherty, M. Green, M. Edmonds, J. Nichol, D. M. Menchaca, B. Cohen, C. G. Begley, Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99, 2599-2602 (2002).
27. M. E. Bromberg, Immune thrombocytopenic purpura - the changing therapeutic landscape. N. Engl. J. Med. 355, 1643-1645 (2006).
28. H. Shiozaki, S. Miyawaki, T. Kuwaki, T. Hagiwara, T. Kato, H. Miyazaki, Autoantibodies neutralizing thrombopoietin in a patient with amegakaryocytic thrombocytopenic purpura. Blood 95, 2187-2188 (2000).
29. S. R. Patel, J. H. Hartwig, J. E. Italiano Jr., The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 115, 3348-3354 (2005).
30. K. Kaushansky, Historical review: Megakaryopoiesis and thrombopoiesis. Blood 111, 981-986 (2008).
31. K. H. Pearce Jr., B. J. Potts, L. G. Presta, L. N. Bald, B. M. Fendly, J. A. Wells, Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites. J. Biol. Chem. 272, 20595-20602 (1997).
32. S. R. Hanson, L. A. Harker, T. D. Bjornsson, Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J. Clin. Invest. 75, 1591-1599 (1985).
33. E. I. Tucker, U. M. Marzec, T. C. White, S. Hurst, S. Rugonyi, O. J. McCarty, D. Gailani, A. Gruber, S. R. Hanson, Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 113, 936-944 (2009).
34. S. R. Hanson, H. F. Kotze, B. Savage, L. A. Harker, Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 5, 595-603 (1985).
35. S. R. Hanson, L. A. Harker, Studies of suloctidil in experimental thrombosis in baboons. Thromb. Haemost. 53, 423-427 (1985).
36. A. B. Lumsden, A. B. Kelly, P. A. Schneider, W. C. Krupski, T. Dodson, S. R. Hanson, L. A. Harker, Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood 81, 1762-1770 (1993).
37. D. M. Wootton, C. P. Markou, S. R. Hanson, D. N. Ku, A mechanistic model of acute platelet accumulation in thrombogenic stenoses. Ann. Biomed. Eng. 29, 321-329 (2001).
38. J. Ramanathan, B. M. Sibai, T. Vu, D. Chauhan, Correlation between bleeding times and platelet counts in women with preeclampsia undergoing cesarean section. Anesthesiology 71, 188-191 (1989).
39. T. Barbui, M. Buelli, S. Cortelazzo, P. Viero, G. De Gaetano, Aspirin and risk of bleeding in patients with thrombocythemia. Am. J. Med. 83, 265-268 (1987).
40. J. W. Hampton, C. Matthews, Similarities between baboon and human blood clotting. J. Appl. Physiol. 21, 1713-1716 (1966).
41. M. E. Todd, E. McDevitt, E. I. Goldsmith, Blood-clotting mechanisms of nonhuman primates. Choice of the baboon model to simulate man. J. Med. Primatol. 1, 132-141 (1972).
42. M. Andrew, V. Castle, S. Saigal, C. Carter, J. G. Kelton, Clinical impact of neonatal thrombocytopenia. J. Pediatr. 110, 457-464 (1987).
43. L. A. Harker, S. J. Slichter, The bleeding time as a screening test for evaluation of platelet function. N. Engl. J. Med. 287, 155-159 (1972).
44. C. H. Mielke Jr., M. M. Kaneshiro, I. A. Maher, J. M. Weiner, S. I. Rapaport, The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34, 204-215 (1969).
45. S. K. Samra, R. L. Harrison, D. E. Bee, V. Valero, A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in humans. Ann. Clin. Lab. Sci. 21, 315-327 (1991).
46. L. W. Gimple, H. K. Gold, R. C. Leinbach, B. S. Coller, W. Werner, T. Yasuda, J. A. Johns, A. A. Ziskind, D. Finkelstein, D. Collen, Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 80, 581-588 (1989).
47. A. Gruber, U. M. Marzec, L. Bush, E. Di Cera, J. A. Fernández, M. A. Berny, E. I. Tucker, O. J. McCarty, J. H. Griffin, S. R. Hanson, Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood 109, 3733-3740 (2007).
48. M. Hayden, M. Pignone, C. Phillips, C. Mulrow, Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 136, 161-172 (2002).
49. M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, S. Schulman, Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 287S-310S (2004).
50. I. F. Ceresa, P. Noris, C. Ambaglio, A. Pecci, C. L. Balduini, Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets 18, 579-582 (2007).
51. C. N. Harrison, P. J. Campbell, G. Buck, K. Wheatley, C. L. East, D. Bareford, B. S. Wilkins, J. D. van der Walt, J. T. Reilly, A. P. Grigg, P. Revell, B. E. Woodcock, A. R. Green; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study, Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353, 33-45 (2005).
52. F. J. de Sauvage, P. E. Hass, S. D. Spencer, B. E. Malloy, A. L. Gurney, S. A. Spencer, W. C. Darbonne, W. J. Henzel, S. C. Wong, W. J. Kuang, K. J. Oles, B. Hultgren, L. A. Solberg Jr., D. V. Goeddel, D. L. Eaton, Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369, 533-538 (1994).
53. S. R. Hanson, J. H. Griffin, L. A. Harker, A. B. Kelly, C. T. Esmon, A. Gruber, Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J. Clin. Invest. 92, 2003-2012 (1993).
54. L. A. Harker, P. Hunt, U. M. Marzec, A. B. Kelly, A. Tomer, S. R. Hanson, R. B. Stead, Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 87, 1833-1844 (1996).
55. L. Schwartz, S. J. Brister, M. G. Bourassa, C. Peniston, M. R. Buchanan, Interobserver reproducibility and biological variability of the Surgicutt II bleeding time. J. Thromb. Thrombolysis 6, 155-158 (1998).
56. T. C. White-Adams, M. A. Berny, E. I. Tucker, J. M. Gertz, D. Gailani, R. T. Urbanus, P. G. de Groot, A. Gruber, O. J. McCarty, Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler. Thromb. Vasc. Biol. 29, 1602-1607 (2009).
57. O. J. McCarty, M. K. Larson, J. M. Auger, N. Kalia, B. T. Atkinson, A. C. Pearce, S. Ruf, R. B. Henderson, V. L. Tybulewicz, L. M. Machesky, S. P. Watson, Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J. Biol. Chem. 280, 39474-39484 (2005).